---
title: "TNET: Q2 2026 saw strong EPS growth and margin expansion, with raised full-year guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294358371.md"
description: "GAAP and adjusted EPS rose sharply year-over-year in Q2 2026, despite a 5% revenue decline. Adjusted EBITDA margin improved to 10.9%, and full-year earnings guidance was raised, reflecting cost management and operational initiatives.Original document: TriNet Group, Inc. [TNET] SEC 8-K Current Report — Jul. 30 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-30T11:41:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294358371.md)
  - [en](https://longbridge.com/en/news/294358371.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294358371.md)
generator: "portal-rs"
---

# TNET: Q2 2026 saw strong EPS growth and margin expansion, with raised full-year guidance

GAAP and adjusted EPS rose sharply year-over-year in Q2 2026, despite a 5% revenue decline. Adjusted EBITDA margin improved to 10.9%, and full-year earnings guidance was raised, reflecting cost management and operational initiatives.

Original document: TriNet Group, Inc. \[TNET\] SEC 8-K Current Report — Jul. 30 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TNET.US](https://longbridge.com/en/quote/TNET.US.md)

## Related News & Research

- [TriNet Chief Revenue Officer Anthony Shea disposes of 1,068 common shares valued at $74,546.4](https://longbridge.com/en/news/296653522.md)
- [TriNet Group (TNET) Could Be 65% Below Fair Value On A Wide DCF Gap](https://longbridge.com/en/news/296250836.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Is Samsung’s $72B payout a vote of confidence in AI?](https://longbridge.com/en/news/296469504.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**